Friday, September 28 |
7:30 am |
Registration Desk Opens & Continental Breakfast
(Lobby, Eric P. Newman Education Center) |
8:00 |
Welcome & Opening Remarks: Setting the Stage for Secondary Prevention Trials in Alzheimer's Disease
John C. Morris, MD, Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University School of Medicine, Director, Knight Alzheimer's Disease Research Center, Washington University School of Medicine |
8:45 |
Mechanisms and Models of Cerebral Amyloidosis
Mathias Jucker, PhD, Hertie-Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative Diseases (DZNE), Tübingen |
9:15 |
Trans-synaptic Propagation of Tauopathy - Anatomic Considerations, Mechanistic Insight and Therapeutic Possibilities
Karen Duff, PhD, Professor, Department of Pathology and Cell Biology Columbia University Medical Center, and Department of Integrative Neuroscience, New York State Psychiatric Institute |
9:45 |
Break |
10:00 |
Adapting Proteostasis to Ameliorate Aggregation-Associated Degenerative Diseases
Jeffery W. Kelly, PhD, Lita Annenberg Hazen Professor of Chemistry, Chairman, Department of Molecular and Experimental Medicine, The Scripps Research Institute |
10:30 |
Development of Statins for Treatment of Hypercholesterolemia
Scott Grundy, MD, PhD, Professor, Distinguished Chair in Human Nutrition, UT Southwestern Medical Center |
11:00 |
Panel
Moderator: David Holtzman, MD, Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, Washington University School of Medicine |
11:30 |
Lunch/Poster Session – Eric P. Newman Center Lobby |
12:15 |
The ‘A4’ Trial: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease
Reisa A. Sperling, MD, Director, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Aging Brain Study, Massachusetts General Hospital, Associate Professor of Neurology, Harvard Medical School |
12:45 |
Alzheimer’s Prevention Initiative
Eric M Reiman, MD, Executive Director, Banner Alzheimer’s Institute |
1:15 |
Dominantly Inherited Alzheimer Network Trials: An Opportunity to Prevent Dementia
Randall J. Bateman, MD, Charles F. and Joanne Knight Distinguished Professor of Neurology, Washington University in St. Louis |
1:45 |
Break |
2:00 |
Clinical Trial Design for Disease-Modifying Treatments for Alzheimer’s Disease: Challenges and Opportunities
Steven M. Paul, MD, Director, Helen and Robert Appel Alzheimer’s Disease Research Institute, Professor of Neuroscience, Psychiatry and Pharmacology,
Weill Cornell Medical College |
2:30 |
Effect of FAD Mutations on the Enzymatic Activity of Gamma-Secretase
Bart De Strooper, MD, PhD, VIB Center for the Biology of Disease, VIB Center for Human Genetics, KU Leuven |
3:00 |
Challenges in Selecting Biomarker Outcomes in AD Clinical Trials
Stephen Salloway, MD, MS, Professor of Neurology and Psychiatry, The Warren Alpert Medical School, Brown University, Director of Neurology and the Memory and Aging Program, Butler Hospital |
3:30 |
Trial Design: Cognitive Outcomes
Laurie Ryan, PhD, Program Director, Alzheimer's Disease Clinical Trials, Division of Neuroscience, National Institute on Aging |
4:00 |
Four Generations of Early Onset Alzheimer’s Disease
Rachel C. Huber and Joe Heinrichs, DIAN Participants |
4:30 |
Panel
Moderator: Alison Goate, DPhil, Professor of Genetics, Department of Psychiatry, Professor of Genetics, Department of Neurology, Neurology, Director, Hope Center for Neurological Disorders, Washington University School of Medicine |
5:00 |
Symposium Closing Reception and Poster Session – Eric P. Newman Center Lobby |
|
|
